# Peru Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Peru HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Peru (PER)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $8.1M
- Products: 26
- Buyer markets: 25
- Average CAGR: +3.3%
- Global sector size: $592.2B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $301.6B | $959.9K | $106.6B | -6.4% | 21 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $96.2B | $524.4K | $36.6B | +35.5% | 5 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $29.5B | $1.4M | $20.3B | +26.9% | 11 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $25.6B | $1.1K | $13.4B | -37.0% | 5 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $13.3B | $14.8K | $12.7B | -4.6% | 4 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $7.9B | $1.2M | $10.7B | +25.1% | 3 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $14.3B | $20.0K | $9.5B | -5.3% | 4 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $16.4B | $27.6K | $9.0B | -24.5% | 4 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $10.1B | $2.0M | $8.9B | +33.1% | 4 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $18.2B | $31.7K | $8.0B | -8.2% | 4 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $17.0B | $109.3K | $7.3B | -0.5% | 4 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $6.9B | $100.7 | $5.0B | -27.0% | 1 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $511.4K | $4.1B | +33.2% | 2 | +0.0% |
| HS 283691 - Carbonates: lithium carbonate | $2.5B | $97.3K | $3.8B | -58.8% | 1 | +0.2% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $3.5B | $1.2K | $3.2B | +3.0% | 1 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $3.1B | $186.2 | $2.9B | +11.1% | 2 | +0.0% |
| HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $80.2 | $2.4B | -51.0% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $3.8B | $4.4K | $2.2B | -1.2% | 2 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $4.2K | $2.0B | +10.0% | 1 | +0.0% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $20.3K | $2.0B | +5.0% | 1 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $1.0M | $1.9B | +44.7% | 1 | +0.1% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $622.8 | $1.4B | -5.1% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $903.6 | $1.4B | -1.7% | 1 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $9.5K | $1.1B | +29.3% | 1 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $2.7B | $65.0K | $1.0B | +55.5% | 1 | +0.0% |
| HS 294190 - Antibiotics: n.e.c. in heading no. 2941 | $883.6M | $5.5K | $990.0M | +10.3% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $80.1B calculated opportunity across 15 products.
- Switzerland, Liechtenstein (CHE): $36.6B calculated opportunity across 4 products.
- Germany (DEU): $26.5B calculated opportunity across 10 products.
- China (CHN): $20.4B calculated opportunity across 7 products.
- Belgium (BEL): $16.1B calculated opportunity across 3 products.
- Netherlands (NLD): $15.7B calculated opportunity across 5 products.
- Spain (ESP): $11.6B calculated opportunity across 6 products.
- Italy (ITA): $9.8B calculated opportunity across 2 products.
- Canada (CAN): $9.0B calculated opportunity across 5 products.
- France (FRA): $7.3B calculated opportunity across 4 products.
- United Kingdom (GBR): $7.3B calculated opportunity across 3 products.
- Mexico (MEX): $6.9B calculated opportunity across 3 products.

## Growth stars

- HS 300290: +55.5% average CAGR, $1.0B calculated opportunity.
- HS 382319: +44.7% average CAGR, $1.9B calculated opportunity.
- HS 300215: +35.5% average CAGR, $36.6B calculated opportunity.
- HS 330300: +33.2% average CAGR, $4.1B calculated opportunity.
- HS 382600: +33.1% average CAGR, $8.9B calculated opportunity.
- HS 321590: +29.3% average CAGR, $1.1B calculated opportunity.
- HS 382499: +26.9% average CAGR, $20.3B calculated opportunity.
- HS 330210: +25.1% average CAGR, $10.7B calculated opportunity.
- HS 293590: +11.1% average CAGR, $2.9B calculated opportunity.
- HS 294190: +10.3% average CAGR, $990.0M calculated opportunity.

## Diversification opportunities

- HS 300490: 21 buyer markets, $106.6B calculated opportunity.
- HS 382499: 11 buyer markets, $20.3B calculated opportunity.
- HS 300215: 5 buyer markets, $36.6B calculated opportunity.
- HS 300212: 5 buyer markets, $13.4B calculated opportunity.
- HS 300220: 4 buyer markets, $12.7B calculated opportunity.
- HS 293499: 4 buyer markets, $9.5B calculated opportunity.
- HS 300439: 4 buyer markets, $9.0B calculated opportunity.
- HS 382600: 4 buyer markets, $8.9B calculated opportunity.
- HS 330499: 4 buyer markets, $8.0B calculated opportunity.
- HS 382200: 4 buyer markets, $7.3B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.